Let’s Recognize the Advances in Lung Cancer this November
Over the past 10 years, tremendous strides have been made in the treatment of lung cancer due in large part due to discoveries of cancer biomarkers such as ALK, EGFR, c-KIT and ROS. In direct correlation, tumors are now classified by their molecular profile resulting in a shift of treatment paradigms and, ultimately better patient outcomes.
View Nov 4, 2019
Transforming Healthcare, Creatively
The seismic shifts in the healthcare industry over the past 5 years have been challenging to navigate but awe-inspiring due to the opportunities they bring. The pace of change will only continue to increase as worldwide as the need for better healthcare and access to that care grow.
View Jun 1, 2019
Learning to Speak HEOR
As one formulary decision-maker told us: “Recent regulation guidance on FDAMA114 frees up pharma to be more active in sharing HEOR information, and I think that helps.”
View Dec 18, 2018